Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
Total Valuation
Candel Therapeutics has a market cap or net worth of $365.50M. The enterprise value is $156.13M.
Market Cap$365.50M
Enterprise Value$156.13M
Share Statistics
Candel Therapeutics has 73,246,925 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding73,246,925
Owned by Insiders9.52%
Owned by Institutions8.21%
Financial Efficiency
Candel Therapeutics’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -41.38%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-41.38%
Return on Capital Employed (ROCE)-0.42
Revenue Per Employee0.00
Profits Per Employee-1.00M
Employee Count38
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Candel Therapeutics is ―. Candel Therapeutics’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio5.76
Price to Fair Value5.76
Price to FCF-7.69
Price to Operating Cash Flow-7.15
PEG Ratio0.13
Income Statement
In the last 12 months, Candel Therapeutics had revenue of 0.00 and earned -38.18M in profits. Earnings per share was -0.72.
Revenue0.00
Gross Profit-845.00K
Operating Income-48.27M
Pretax Income-38.18M
Net Income-38.18M
EBITDA-47.42M
Earnings Per Share (EPS)-0.72
Cash Flow
In the last 12 months, operating cash flow was -38.31M and capital expenditures -587.00K, giving a free cash flow of -38.90M billion.
Operating Cash Flow-38.31M
Free Cash Flow-38.90M
Free Cash Flow per Share-0.53
Dividends & Yields
Candel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change-43.49%
50-Day Moving Average5.56
200-Day Moving Average5.54
Relative Strength Index (RSI)44.42
Average Volume (3m)1.28M
Important Dates
Candel Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Candel Therapeutics as a current ratio of 13.31, with Debt / Equity ratio of 3.67%
Current Ratio13.31
Quick Ratio13.31
Debt to Market Cap<0.01
Net Debt to EBITDA2.48
Interest Coverage Ratio-22.78
Taxes
In the past 12 months, Candel Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Candel Therapeutics EV to EBITDA ratio is -3.83, with an EV/FCF ratio of -4.66.
EV to Sales0.00
EV to EBITDA-3.83
EV to Free Cash Flow-4.66
EV to Operating Cash Flow-4.73
Balance Sheet
Candel Therapeutics has $119.73M in cash and marketable securities with $1.90M in debt, giving a net cash position of $117.83M billion.
Cash & Marketable Securities$119.73M
Total Debt$1.90M
Net Cash$117.83M
Net Cash Per Share$1.61
Tangible Book Value Per Share$0.98
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Candel Therapeutics is $18.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.60
Price Target Upside272.75% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast68.53%